Week In Review: Sinopharm Transfers $4.6 Billion In Assets, Including Two COVID-19 Vaccines

person holding black round plate

Image Source: Unsplash

COVID-19 Pandemic 

Sinopharm Group (SHTDF), China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products (SHA: 600161), a Shanghai-listed biopharma that is 50% owned by Sinopharm (see story).

Two of the transferring companies have approved COVID-19 vaccines, and Sinopharma said a public listing will facilitate additional sources of funding for all of the assets. Sinopharm put a $4.6 billion valuation on the six companies. Tiantan is a biologics company with a current market capitalization of $7 billion that offers blood-based products and vaccines.

Deals and Financings

1 2 3
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.